LEO 32731

Drug Profile

LEO 32731

Alternative Names: LEO32731; LP-0058

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Pharma
  • Class Antipsoriatics
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 10 stimulants; Interleukin 5 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I Atopic dermatitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis(In volunteers) in United Kingdom (PO, Controlled release)
  • 22 Aug 2017 LEO Pharma completes a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT03231124)
  • 25 Jul 2017 LEO Pharma initiates enrolment in a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT03231124)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top